Merrimack and Baxalta Announce Enrollment of First Patient in Phase 2 Study of ONIVYDE™ (irinotecan liposome injection) in Previously Untreated Front-line Metastatic Pancreatic Cancer

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. MU
3. FDX
4. SPY
5. META
6. ABBV
7. NVDA
8. BLZE
9. IBM
10. NKE

Go back to Merrimack and Baxalta Announce Enrollment of First Patient in Phase 2 Study of ONIVYDE™ (irinotecan liposome injection) in Previously Untreated Front-line Metastatic Pancreatic Cancer

Merrimack Pharmaceuticals (MACK) PT Raised to $15 at Oppenheimer

October 27, 2015 8:17 AM EDT

Oppenheimer analyst Ling Wang reiterated an Outperform rating and boosted her price target on Merrimack Pharmaceuticals (NASDAQ: MACK) to $15.00 (from $13.00) after the FDA approved Onivyde (irinotecan liposome injection, or MM-398) in combination with fluorouracil (5-FU) and leucovorin (5-FU/LV) for the treatment of metastatic pancreatic... More